Three Directors at Galectin Therapeutics Inc sold after exercising options/sold 51,770 shares at between 7.038USD and 7.056USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades ...
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that the U.S. Food and Drug Administration (FDA) has provided a written response, and subsequent communications, to the Company’s previously submitted Type C meeting request rega...
A director at Phibro Animal Health Corp sold 7,040 shares at 42.099USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Ewa M. Stasiowska Joins Live Oak Bank as Chief Risk Officer WILMINGTON, N.C., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Live Oak Bancshares announced today that Ewa M. Stasiowska has been named Chief Risk Officer (CRO) of the company. Stasiowska also assumes the role of CRO of Live Oak Bank. Stasiowska is a senior risk management executive with more than two decades of experience overseeing enterprise, financial, operational, and model risk functions within regulated financial institutions. Previously, she was Senior Managing Director at Webster Bank, where she was responsible for Enterprise, Mo...
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and nine months ended September 30, 2025. “The new NAVIGATE data presented at AASLD further strengthen the clinical and mechanistic profile of belapectin. We continue to see encouraging consistency across key biomarkers—including FibroScan®, ELF, and PRO-C3—all ...
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting New biomarker analyses from the NAVIGATE trial demonstrated consistent antifibrotic effects of belapectin 2 mg/kgUsing established criteria for clinically meaningful worsening, a lower proportion of patients treated with belapectin 2 mg/kg experienced ≥30% or ≥5 kPa increases in liver stiffness (LSM) by FibroScan® compared with placebo, indicating slowing of fibrosis progression and stabilization of liver functionAcross all ELF fibrosis risk categori...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Live Oak Bancshares, Inc. Reports Third Quarter 2025 Results WILMINGTON, N.C., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Live Oak Bancshares, Inc. (NYSE: LOB) (“Live Oak” or “the Company”) today reported third quarter of 2025 net income attributable to common shareholders of $25.6 million, or $0.55 per diluted common share. Live Oak’s performance in the quarter, compared to the second quarter of 2025 and third quarter of 2024, includes these notable items: Strong loan production of $1.65 billion accompanied by strong deposit growth of $695.9 million in the third quarter of 2025, with total asse...
Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference NORCROSS, Ga., Oct. 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will participate in the H.C. Wainwright 9th Annual MASH Virtual Investor Conference, taking place October 21, 2025. H.C. Wainwright 9th Annual MASH Investor ConferenceCompany presentation: October 21, 2025, at 7:00 AM ETWebcast: The live and archived webcast will also be available on the page in the investors section of ...
Live Oak Bancshares, Inc. Announces Date of Third Quarter 2025 Financial Results WILMINGTON, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Live Oak Bancshares, Inc. (NYSE: LOB) today announced that it will report its third quarter 2025 financial results after U.S. financial markets close on Wednesday, October 22, 2025. In conjunction with this announcement, Live Oak will host a conference call to discuss the company's financial results and business outlook on Thursday, October 23, 2025, at 9:00 a.m. ET. The call will be accessible by telephone and webcast using Conference ID: 72227. A supplem...
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025 NORCROSS, Ga., Oct. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced participation in the AASLD Liver Meeting 2025. The company will deliver two presentations, including one oral and one poster presentation, highlighting data from the NAVIGATE trial assessing belapectin for the treatment of MASH cirrhosis. The meeting will be held November 7-...
Live Oak Bank Leads Nation in SBA 7(a) Lending Activity WILMINGTON, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Live Oak Bank has been named the most active SBA 7(a) lender by dollar amount by the U.S. Small Business Administration. The results are posted to the and display the country’s top SBA 7(a) lenders by dollar amount and loan volume for the administration’s 2025 fiscal year, which ended September 30, 2025. “The SBA 7(a) program continues to be a vital resource for American small business owners seeking access to capital,” said James S. (Chip) Mahan III, Chairman and CEO of Live Oak...
Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will participate in the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in New York, NY. H.C. Wainwright 27th Annual Global Investment ConferenceCompany presentation: September 8, 2025, at 1:00 PM ET. Webcast: The live and archived webcast will also be available on the pa...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.